載入...
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
BACKGROUND: The 12-week, phase III Pulmonary Arterial hyperTENsion sGC-stimulator Trial (PATENT)-1 study investigated riociguat in patients with pulmonary arterial hypertension (PAH). Here, we present a prospectively planned analysis of the safety and efficacy of riociguat in the subgroup of patient...
Na minha lista:
| 發表在: | Ann Rheum Dis |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5284330/ https://ncbi.nlm.nih.gov/pubmed/27457511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-209087 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|